Week of Mar. 26, 2012: Catalent Completes UK Expansion; Novasep Opens New Facility in China; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Mar. 26, 2012: Catalent Completes UK Expansion; Novasep Opens New Facility in China; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Abbott has announced that AbbVie will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. The naming of the new company is the latest milestone in the process that began in October 2011, when Abbott announced it would separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. AbbVie will include Abbott’s current portfolio of proprietary pharmaceuticals and biologics. Read More

Catalent Pharma Solutions has completed its new development and analytical solutions’ laboratories at its facility in Swindon, United Kingdom. From this new laboratory suite, Catalent will offer analytical testing, development support, and regulatory services to pharmaceutical and biopharmaceutical companies. The laboratory suite incorporates expanded facilities for the storage and testing of controlled and cytotoxic substances. Catalent’s new Swindon laboratories offer a comprehensive range of development and analytical services. These services include European import testing, qualified person and regulatory consulting services, methods development, and microbial, sterility, and stability testing for a range of advanced-dose forms, including for inhaled and orally administered substances. Read More

Novasep, a supplier of manufacturing solutions to the life-sciences industries, has opened a new 2000-m2 (21,527.820 ft2) facility in Shanghai, China. The site is intended to increase Novasep’s process-development and engineering capabilities to meet increasing Chinese and East Asian demand. The facilities will also add to Novasep’s existing 12 global synthesis and process sites in the US, France, Germany, Belgium, and the Bahamas. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here